[English]  [Pусский]  [中文]  
ctt-journal > Vavilov 2 et al. (Abstract)

Vavilov 2 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract70
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


An investigation into invasive aspergillosis prophylaxis in children with acute lymphoblastic leukemia receiving polychemotherapy protocols

Vladimir N. Vavilov, Andrey V. Kozlov, Natalya V. Stancheva, Elena V. Semenova, Ludmila S. Zubarovskaya

R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, Pavlov State Medical University, Saint-Petersburg, Russia

Correspondence: Vladimir N. Vavilov, R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, Saint-Petersburg Pavlov State Medical University, 6/8, Tolstoy str., Saint-Petersburg, 197022, Russia, E-mail: vladimir_vavilov@spam is badmail.ru


Introduction: Currently, invasive aspergillosis (IA) prophylaxis is routinely included in acute myeloid leukemia treatment protocols. At the same time acute lymphoid leukemia (ALL) chemotherapy may also be associated with the increased risk of IA.

The aim of our study was to assume the validity of IA prophylaxis in the supportive treatment of ALL patients during induction of remission and consolidation treatment.

Material and methods: Twenty-one patients with newly diagnosed ALL were included in the investigation.

Patients received chemotherapy according to international protocols. The diagnosis of IA was based on the presence of aspergillus antigen galactomannan in the blood, bronchoalveolar lavage, liquor, and computer tomography data.

Results: IA during the induction and consolidation treatment phase of ALL was diagnosed in 14 patients (67%). During consolidation treatment 6 cases (43%), and during induction treatment 5 cases (36%) of IA were diagnosed. In 3 patients (14%) IA was diagnosed before the onset of chemotherapy or on maintenance therapy. The frequency of proven invasive aspergillosis was 0%, frequency of probable invasive aspergillosis was 21% and frequency of possible invasive aspergillosis was 79%. Attributive lethality was 0%.

Conclusion: Invasive aspergillosis is an important complication in ALL chemotherapy treatment that can affect the therapy schedule. AI prophylaxis during induction and consolidation treatment can possibly reduce the risk of its occurrence. The low frequency of proven and probable aspergillosis and the low lethality in this group of patients calls for further investigation.

Keywords: acute leukemia, invasive aspergillosis


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment